{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:06:51Z","timestamp":1780999611248,"version":"3.54.1"},"reference-count":61,"publisher":"BMJ","issue":"5","funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["755094"],"award-info":[{"award-number":["755094"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:p>We analysed clinical trials of pharmacological interventions on patients with amyotrophic lateral sclerosis (ALS), and compared study quality and design features. The systematic review included articles published in PubMed and trials registered in ClinicalTrials.gov. Included studies were randomised double-blind placebo-controlled clinical trials assessing a disease-modifying pharmacological intervention. Studies were excluded if primary end points were safety or dose finding. A total of 28 735 articles and 721 current trials were identified. 76 published articles and 23 ongoing trials met inclusion criteria; they referred to distinct populations comprising 22 817 participants with ALS. Most articles and all current trials had parallel group design; few articles had cross-over design. A run-in observation period was included in about 20% of published studies and ongoing trials. Primary end points included functional assessment, survival, muscle strength, respiratory function, biomarkers and composite measures. Most recent trials had only functional assessment and survival. Risk of bias was high in 23 articles, moderate in 35, low in 18. A disease modification effect was observed for 10 interventions in phase II studies, two of which were confirmed in phase III. Three confirmatory phase III studies are currently underway. The present review provides cues for the design of future trials. Functional decline and survival, as single or composite measures, stand as the reference end points. Post hoc analyses should not be performed, particularly in studies using composite end points. There is a general agreement on diagnostic criteria; but eligibility criteria must be improved. Run-in observations may be used for censoring patients but are discouraged for refining participants\u2019 eligibility. The ALS Functional Rating Scale-Revised needs improvement for use as an ordinal measure of functional decline.<\/jats:p>","DOI":"10.1136\/jnnp-2021-328470","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T18:25:41Z","timestamp":1646072741000},"page":"521-529","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Review of disease-modifying drug trials in amyotrophic lateral sclerosis"],"prefix":"10.1136","volume":"93","clinical-trial-number":[{"clinical-trial-number":"nct03800524","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03127267","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05021536","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03800524","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0252-8007","authenticated-orcid":false,"given":"Paolo","family":"Tornese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Lalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoniangela","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5864-0006","authenticated-orcid":false,"given":"Alberto","family":"Albanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"2023051800301771000_93.5.521.1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/B978-0-12-802973-2.00013-6","article-title":"The epidemiology of amyotrophic lateral sclerosis","volume":"138","author":"Talbott","year":"2016","journal-title":"Handb Clin Neurol"},{"key":"2023051800301771000_93.5.521.2","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/WCO.0000000000000730","article-title":"Epidemiology of amyotrophic lateral sclerosis: an update of recent literature","volume":"32","author":"Longinetti","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"2023051800301771000_93.5.521.3","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617734734","article-title":"Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis","volume":"11","author":"Dorst","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"2023051800301771000_93.5.521.4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/med.21528","article-title":"Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs","volume":"39","author":"Jaiswal","year":"2019","journal-title":"Med Res Rev"},{"key":"2023051800301771000_93.5.521.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(99)00209-9"},{"key":"2023051800301771000_93.5.521.6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/14660820410020187","article-title":"Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial","volume":"5","author":"Leigh","year":"2004","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"2023051800301771000_93.5.521.7","unstructured":"European Medicines Agency . Guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis (ALS). (CHMP) CfMPfHU ed. London: European Medicines Agency, 2015: 1\u201321."},{"key":"2023051800301771000_93.5.521.8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007242"},{"key":"2023051800301771000_93.5.521.9","unstructured":"Food and Drug Administration . Amyotrophic lateral sclerosis: developing drugs for treatment. guidance for industry. Services USDoHaH, ed. Washington DC: Food and Drug Administration, 2019: 1\u20138."},{"key":"2023051800301771000_93.5.521.10","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"2023051800301771000_93.5.521.11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1080\/14660820510011997","article-title":"Clinical trials in ALS: a review of the role of clinical and neurophysiological measurements","volume":"6","author":"de Carvalho","year":"2005","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"2023051800301771000_93.5.521.12","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/WCO.0000000000000861","article-title":"Current trends in the clinical trial landscape for amyotrophic lateral sclerosis","volume":"33","author":"van Eijk","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"2023051800301771000_93.5.521.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"2023051800301771000_93.5.521.14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2023051800301771000_93.5.521.15","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis","volume":"330","author":"Bensimon","year":"1994","journal-title":"N Engl J Med Overseas Ed"},{"key":"2023051800301771000_93.5.521.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91680-3"},{"key":"2023051800301771000_93.5.521.17","doi-asserted-by":"publisher","DOI":"10.1007\/s004150200071"},{"key":"2023051800301771000_93.5.521.18","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3109\/21678421.2014.959024","article-title":"Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients","volume":"15","author":"Abe","year":"2014","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"2023051800301771000_93.5.521.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30115-1"},{"key":"2023051800301771000_93.5.521.20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/21678421.2017.1361441","article-title":"Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: grade 3, requiring assistance for eating, excretion or ambulation)","volume":"18","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"2023051800301771000_93.5.521.21","doi-asserted-by":"publisher","DOI":"10.1080\/146608200300079536"},{"key":"2023051800301771000_93.5.521.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2007.09.143"},{"key":"2023051800301771000_93.5.521.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2020.04.005"},{"key":"2023051800301771000_93.5.521.24","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-016-1451-9","article-title":"Randomized controlled trials: who fails run-in?","volume":"17","author":"Rees","year":"2016","journal-title":"Trials"},{"key":"2023051800301771000_93.5.521.25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/CLEP.S188752","article-title":"Randomized clinical trials with run-in periods: frequency, characteristics and reporting","volume":"11","author":"Laursen","year":"2019","journal-title":"Clin Epidemiol"},{"key":"2023051800301771000_93.5.521.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17670-8"},{"key":"2023051800301771000_93.5.521.27","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000006855","article-title":"Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials","author":"van Eijk","year":"2019","journal-title":"Neurology"},{"key":"2023051800301771000_93.5.521.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30089-9"},{"key":"2023051800301771000_93.5.521.29","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012545"},{"key":"2023051800301771000_93.5.521.30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/17434470410020021","article-title":"ALS endpoints. survival","volume":"5 Suppl 1","author":"Cedarbaum","year":"2004","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"2023051800301771000_93.5.521.31","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1080\/146608202320374246","article-title":"Survival endpoint: con","volume":"3 Suppl 1","author":"Rosenfeld","year":"2002","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"2023051800301771000_93.5.521.32","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1080\/146608202320374237","article-title":"Survival endpoint: pro","volume":"3 Suppl 1","author":"Bensimon","year":"2002","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"2023051800301771000_93.5.521.33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/CLEP.S153196","article-title":"Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis","volume":"10","author":"van Eijk","year":"2018","journal-title":"Clin Epidemiol"},{"key":"2023051800301771000_93.5.521.34","doi-asserted-by":"publisher","DOI":"10.3109\/21678421.2012.762930"},{"key":"2023051800301771000_93.5.521.35","doi-asserted-by":"crossref","first-page":"605","DOI":"10.4155\/cli.14.52","article-title":"Outcome measures in amyotrophic lateral sclerosis clinical trials","volume":"4","author":"Paganoni","year":"2014","journal-title":"Clin Investig"},{"key":"2023051800301771000_93.5.521.36","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000581"},{"key":"2023051800301771000_93.5.521.37","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-021-02187-8","article-title":"Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study","volume":"21","author":"Kj\u00e6ldgaard","year":"2021","journal-title":"BMC Neurol"},{"key":"2023051800301771000_93.5.521.38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jclinepi.2020.07.017","article-title":"Composite endpoints","volume":"128","author":"Palileo-Villanueva","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"2023051800301771000_93.5.521.39","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26801"},{"key":"2023051800301771000_93.5.521.40","doi-asserted-by":"publisher","DOI":"10.1159\/000089316"},{"key":"2023051800301771000_93.5.521.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2008.07.016"},{"key":"2023051800301771000_93.5.521.42","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-314661"},{"key":"2023051800301771000_93.5.521.43","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006317"},{"key":"2023051800301771000_93.5.521.44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2011.03540.x"},{"key":"2023051800301771000_93.5.521.45","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-014-0322-x"},{"key":"2023051800301771000_93.5.521.46","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/21678421.2013.838970","article-title":"Pooled resource open-access ACTC. amyotrophic lateral sclerosis disease progression model","volume":"15","author":"Gomeni","year":"2014","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"2023051800301771000_93.5.521.47","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-304701"},{"key":"2023051800301771000_93.5.521.48","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-010-5609-1"},{"key":"2023051800301771000_93.5.521.49","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1212\/WNL.24.8.721","article-title":"The administration of guanidine in amyotrophic lateral sclerosis","volume":"24","author":"Norris","year":"1974","journal-title":"Neurology"},{"key":"2023051800301771000_93.5.521.50","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410220308"},{"key":"2023051800301771000_93.5.521.51","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1007\/s11136-014-0730-8","article-title":"Longitudinal quality of life data: a comparison of continuous and ordinal approaches","volume":"23","author":"Donneau","year":"2014","journal-title":"Qual Life Res"},{"key":"2023051800301771000_93.5.521.52","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3109\/21678421.2016.1140786","article-title":"The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset","volume":"17","author":"Proudfoot","year":"2016","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"2023051800301771000_93.5.521.53","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3280"},{"key":"2023051800301771000_93.5.521.54","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12664"},{"key":"2023051800301771000_93.5.521.55","doi-asserted-by":"publisher","DOI":"10.3109\/17482960903093710"},{"key":"2023051800301771000_93.5.521.56","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-153-3-201008030-00006"},{"key":"2023051800301771000_93.5.521.57","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1474-4422(18)30176-5","article-title":"Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial","volume":"17","author":"Ludolph","year":"2018","journal-title":"Lancet Neurol"},{"key":"2023051800301771000_93.5.521.58","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-319294"},{"key":"2023051800301771000_93.5.521.59","doi-asserted-by":"publisher","DOI":"10.1177\/1740774509102563"},{"key":"2023051800301771000_93.5.521.60","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/ncpneuro0618","article-title":"Publication bias against negative results from clinical trials: three of the seven deadly sins","volume":"3","author":"Johnson","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"key":"2023051800301771000_93.5.521.61","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-018-5293-7"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2021-328470","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T07:33:56Z","timestamp":1684395236000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2021-328470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":61,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,4,12]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/jnnp-2021-328470"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2021-328470","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]}}}